Dafna Capital Management LLC Aerie Pharmaceuticals Inc Transaction History

Dafna Capital Management LLC

$389 Million
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $115,883 - $277,064	18,192 Added 6.29%	307,232 $4.65 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $200,112 - $250,403	13,200 Added 4.79%	289,040 $4.63 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $165,312 - $263,340	-12,600 Reduced 4.37%	275,840 $4.93 Million
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $36,480 - $57,960	4,000 Added 1.41%	288,440 $3.9 Million
Q3 2020 Nov 16, 2020	BUY	$10.46 - $14.46 $52,300 - $72,300	5,000 Added 1.79%	284,440 $3.35 Million
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $168,000 - $225,820	-14,000 Reduced 4.77%	279,440 $4.13 Million
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $303,115 - $653,337	25,601 Added 9.56%	293,440 $3.96 Million
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $352,787 - $499,715	-19,909 Reduced 6.92%	267,839 $6.47 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $1.52 Million - $2.3 Million	82,308 Added 40.06%	287,748 $5.53 Million
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $1.55 Million - $2.59 Million	53,670 Added 35.36%	205,440 $6.07 Million
Q1 2019 May 15, 2019	BUY	$36.32 - $49.25 $363,200 - $492,500	10,000 Added 7.05%	151,770 $7.21 Million
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $297,000 - $540,360	9,000 Added 6.78%	141,770 $5.12 Million
Q3 2018 Nov 14, 2018	BUY	$56.15 - $73.9 $56,150 - $73,900	1,000 Added 0.76%	132,770 $8.17 Million
Q2 2018 Aug 13, 2018	SELL	$47.85 - $70.45 $47,850 - $70,450	-1,000 Reduced 0.75%	131,770 $8.9 Million
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $818,400 - $976,000	16,000 Added 13.7%	132,770 $7.2 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $5.68 Million - $7.02 Million	116,770	116,770 $5.68 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account